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Original Article
The Efficacy of Puromycin and Adriamycin for Induction
of Glomerular Failure in Larval Zebrafish Validated
by an Assay of Glomerular Permeability Dynamics
Sebastien Andrew Rider,1 Finnius Austin Bruton,1 Richard George Collins,2
Bryan Ronald Conway,1 and John James Mullins1
Abstract
Defects in the glomerular filtration barrier (GFB) play amajor role in the onset of human renal diseases.Highly ramified
glomerular cells named podocytes are a critical component of the GFB. Injury to podocytes results in abnormal
excretionofplasmaproteins,which can lead to chronic kidneydisease.The conservedpairednephronof larval zebrafish
is an excellent model for assessing glomerular function and injury. The efficacy of two known podocyte toxins was
tested to refinemodels of acute podocyte injury in larval zebrafish.Thevalidated compoundwas thenused to test anovel
assay of the dynamics of abnormal protein excretion. Injected adriamycin was found to be unsuitable for induction of
glomerular injury due to off-target cardiovascular toxicity. In contrast, puromycin treatment resulted in a loss of
discriminative filtration, measured by excretion of 70kDa dextran, and podocyte effacement confirmed by electron
microscopy. The dynamics of dextran excretion during puromycin injury modeled the onset of glomerular damage
within 24 hours postinjection. These data validate puromycin for induction of acute podocyte injury in zebrafish larvae
and describe a semihigh-throughput assay for quantifying the dynamics of abnormal protein excretion.
Keywords: puromycin, adriamycin, podocyte, glomerulus, pharmacological, kidney
Introduction
Approximately 1 million glomeruli filter 90 L of bloodin each human kidney every day.1 The precise filtration
of blood constituents depends on the maintained integrity of
the glomerular filtration barrier (GFB). The GFB comprises
two highly specialized cell types separated by a type IV
collagen and laminin-rich glomerular basement membrane
(GBM).2 The fenestrated endothelium forming the walls of
glomerular capillaries is enwrapped by podocytes. Podocytes
are highly ramified epithelial cells with primary and sec-
ondary foot processes, the structure of which depends on their
actin cytoskeleton.3 The filtration slits between interdigitated
podocyte foot processes comprise highly specialized gap
junctions called slit diaphragms (SDs). The SD protein
complex forms the barrier to protein filtration and is essential
for maintained podocyte structure and function.4
All identified monogenic mutations associated with ne-
phrotic syndrome are in podocyte-specific genes, revealing
the essential role of these specialized cells for glomerular
function. Disease-causing recessive or dominant autosomal
mutations have been identified, among others, in nephrin
(NPHS1),5 transient receptor potential channel 6 (TRPC6),6
Wilm’s tumor suppressor gene 1 (WT1),7 and podocin
(NPHS2).8 Most glomerular injuries are, however, not he-
reditary, but acquired in immune or nonimmune diseases,
with 75% of cases having an unknown cause.9
Podocyte effacement, the gradual simplification of the
interdigitating foot process pattern, is a key pathology com-
mon to most glomerular diseases.9,10 The breakdown of the
GFB in disease, or as a result of drug toxicity, causes pro-
teinuria, the abnormal filtration of plasma proteins, including
albumin. Proteinuria associated with nephrotic syndrome
results in edema, likely due to increased sodium retention by
the distal nephron.11
Experimental animal models are required that recapitulate
the molecular events that manifest during glomerular injury
and the sequelae of pathological responses that lead to
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glomerulosclerosis and the loss of functioning glomeruli.9 In
rodents, acute nephrosis may be experimentally induced
through insult to podocytes by nephrotoxic compounds. Injec-
tion of the antibiotic, puromycin aminonucleoside (PAN),
causes either a mild or reversible glomerular damage resem-
bling minimal change disease, or more severe lesions that mi-
mic human focal segmental glomerulosclerosis (FSGS),12,13 the
latter a hallmark of lasting and progressively damaging chronic
kidney diseases.14 Similarly, a single injection of the chemo-
therapy drug, adriamycin, causes a severe form of FSGS in rats
and mice.15
With its unique set of experimental advantages, including
genetic tractability and unparalleled opportunity for in vivo
experimentation, zebrafish have become a valuable animal
model for renal research. The small size, rapid development,
and translucency of larval zebrafish offer excellent opportu-
nities for whole-animal chemical and genetic screening16
and, recently, for studies of renal cancer.17–21 Within the first
3 days of life, the pronephros of larval fish becomes func-
tional and capable of discriminative filtration.22,23 Mature
pronephric podocytes in larval zebrafish are anatomically
similar to their mammalian counterparts and are nonmigra-
tory, including during repair.24–26 With a developed glo-
merulus, segmented tubules, and renin-expressing cells, the
single paired nephron of the zebrafish pronephros shares
remarkable anatomical and functional similarity with the
metanephric mammalian nephron.22,23,27–33
Due to inherent limitations in current methods, the zebrafish
model requires novel and refined renal injury techniqiues.34 A
particular drawback to pharmacological models of acute renal
failure in larval fish is that they are terminal, which limits the
potential for follow-up studies.34 Genetic approaches for in-
duction of glomerular injury have successfully utilized ni-
troreductase (NTR)35–37 to induce ablation of podocytes by
cytotoxic metabolization of metronidazole (MTZ).38 This re-
capitulates proteinuria and has been successfully used to
demonstrate the regenerative capacity of fish podocytes post-
injury.25,35,37 However, the NTR/MTZ system is limited by
side effects of MTZ and the prolonged time required for in-
duction of apoptosis.
While also often limited by off-target effects, pharmaco-
logical approaches are quick to implement and may be ap-
plied to a variety of wild-type or transgenic lines. Current
methods for the pharmacological disruption of podocytes in
zebrafish utilizing puromycin result in an increased glomer-
ular permeability.39 A comparison of pharmacological agents
for induction of podocyte injury in zebrafish is required to
identify compounds exhibiting the greatest potency with the
lowest off-target effects.
The aims of the present study were twofold, (1) to compare
puromycin and adriamycin for pharmacological induction of
glomerular injury in zebrafish larvae with an established GFB
and (2) to develop a high-throughput assay to measure the
in vivo dynamics of abnormal protein excretion.
Adriamycin and puromycin were tested for their ability to
induce structural podocyte damage and increased glomerular
permeability. Increased permeability was determined by the
excretion of normally retained dextran, and changes in podo-
cyte morphology were assessed by transmission electron mi-
croscopy (TEM). As glomerular function is tightly associated
with cardiovascular function in larval fish,40 the effects of
these compounds on heart rate and blood flowwere also tested.
After validating a puromycin model of glomerular injury, a
novel dextran excretion assay was developed to assay the
dynamics of glomerular permeability. Our study provides both
a defined pharmacological model of acute podocyte injury and
a novel assay enabling the measurement of protein excretion
dynamics during glomerular injury and repair.
Materials and Methods
Zebrafish and husbandry
All experiments utilizing fish >5 dpf (days postfertilization)
were approved by the local ethics committee and conducted in
accordance with the Animals (Scientific Procedures) Act 1986
in a UK Home Office-approved establishment. Unless stated
otherwise, wild-type WIK zebrafish (Danio rerio) were main-
tained at 28.5C in 1· conditioned water (CW)40 containing
0.1% (w/v) methylene blue. Where required, fish were an-
esthetized in CW containing 40 lg mL-1 MS-222 (tricaine
methanesulfonate). Forty micrograms per milliliter MS-222
is sufficient for anesthesia without significant effects on the
heart rate.41Microinjections andmicroscopy were carried out
at room temperature (26C – 0.5C).
Microinjection of dextran and pharmacological agents
Dextran and pharmacological agents were administered
under anesthesia by intravenous microinjection through the
cardiac sinus venosus (SV) that drains the common cardinal
vein (CCV).42 All injections were administered in a 1-nL
volume. A successful injection was determined as a 100%
delivery into the cardiovascular system. Injections where
solutions ended up in the yolk, or in the pericardial sac, were
deemed as unsuccessful; 5% (w/v) 70 kDa FITC-dextran was
dissolved in phosphate-buffered saline (PBS). PAN (#15509;
Cayman Chemical Company) was administered at 5 or 25mg
mL-1 (17.0–85.0mM) and adriamycin (doxorubicin hydro-
chloride) (#15007; Cayman Chemical Company) at 1, 2, or
4mgmL-1 (1.7, 3.4, 6.9mM). Shams were administered with
vehicle (PBS) only.
Determination of the dose for induction
of glomerular injury
Three dpf fish were injected respective treatment com-
pounds, or vehicle (PBS), and separated into Petri dishes in
triplicate. Fish were examined immediately after injection
and at 24 and 48 hpi (hours postinjection). At each time point,
fish were scored for percentage survival and overt pericardial
sac edema.
Dextran clearance assay
The clearance of 70 kDa FITC-dextran was determined
by measuring fluorescence intensity in the dorsal aorta.
In summary, postinjection, fish recovered in CW (without
methylene blue) before brief anesthesia and mounting in 3%
methylcellulose for baseline imaging at 3 hpi. Sagittal images
of FITC fluorescence in the dorsal aorta were taken using a
stereomicroscope with fixed parameters. Embryos were re-
turned to CW and standard conditions immediately after each
imaging time point. For each fish, the mean intensity of three
areas of the dorsal aorta was measured using Fiji—National
Institutes of Health (NIH). Mean fluorescence intensity
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values were normalized against the baseline fluorescence and
percentage intensity change was calculated.
Heart rate and venous erythrocyte velocity
After respective treatments, 3 dpf embryos were left to
recover in CW for three hours before mounting in 3%
methylcellulose and immediate imaging under anesthesia.
Bright-field videos over 120 s in length were acquired of the
dorsal aorta at 50 frames per second. Single erythrocytes
were then tracked through the cardinal vein anterior of the
cloaca. The distance traveled by three erythrocytes per em-
bryo was measured using Fiji and venous erythrocyte ve-
locity calculated in lm s-1. Heart rate was assessed similarly
by recording the video at a frame rate of 10 frames per second
and heartbeats counted manually over a 10-s period. Both
videos were taken of a lateral orientation.
Dextran excretion assay in a modified 96-well plate
Postinjection, fishwere left to recover for 1 h in CW (without
methylene blue) before distribution into a modified black, flat-
bottomed, 96-well Microfluor 1 plate (Nunc). Two hundred
fifty-micrometer slits were used to create 48 paired wells
(Fig. 4A). In each well pair, one well contained a single fish,
leaving the second well free for measurements of FITC in-
tensity in the CW (Fig. 4B). The two well pairs were filled with
*790lL CW (without methylene blue) and covered with real-
time polymerase chain reaction (qPCR) (Sarstedt) film, leav-
ing no air gap between the water and film. FITC intensity was
read once every 15min for 48 h at a kex of 485 nm and kem of
535 nm. At the end of each assay, fish survival was confirmed.
TEM and image analysis
Three dpf fish were injected with 25mg mL-1 puromycin
or vehicle. At 8 and 24 hpi, fish were fixed for TEM as de-
scribed by Lyons et al.43 Briefly, fish were fixed in modified
Karnovsky’s solution (2% glutaraldehyde and 4% parafor-
maldehyde in 0.1M sodium cacodylate buffer), postfixed in
2% osmium tetroxide in 0.1M imidazole and 0.1M sodium
cacodylate, stained en bloc in saturated uranyl acetate, and
dehydrated into 100% acetone. All of these steps were ac-
celerated using microwave stimulation with a Panasonic
microwave with inverter technology. Temperature through-
out was maintained at 15C in a cooled water bath. Following
dehydration, embryos were embedded in Epon. Ultrathin
sections (60 nm thick) were cut from selected areas and
mounted on Formvar/carbon-coated copper slot grids. After
drying, these were stained in 1% aqueous uranyl acetate and
Reynold’s lead citrate, and then viewed in a JEOL JEM-1400
Plus TEM.
Representative images were collected on a GATAN One-
View camera for analysis of GFB structural changes using Fiji,
as similarly performed by Benchimol de Souza et al.44 The
mean podocyte frequency per lm length (of basement mem-
brane) andmean podocytewidth were determined in all clearly
identifiable sections of the GFB (Fig. 3A).
Statistical analysis
All data were statistically analyzed and graphed with
GraphPad Prism 7 (La Jolla, CA). All percentage data were
arcsine transformed before analysis. Dextran clearance from
the dorsal aorta, heart rate, and blood flow were subjected to
two-way ANOVA. Foot process width and foot process
number per lm GBM were analyzed by one-way ANOVA.
Dextran excretion data were analyzed by linear regression
and comparison of regression slopes. The first derivative of
excretion data was determined for individual fish. Differ-
ences between the mean first derivative of control and
treatment groups were determined for measures between
0–24 hpi and 24–48 hpi using t-tests. All means are reported
with a standard error of the mean.
Results
Determination of doses for induction
of pharmacological injury
The dose of a single intravenous injection of puromycin or
adriamycin required to cause edema without effects on sur-
vival was tested. Achieving successful intravenous injections
is considerably easier, and consequently more accurate, in
3 dpf fish due to the large CCV and SV. Due to a narrowing of
the CCV by 4 dpf, injections in older larval fish are much
more challenging and error prone. Adriamycin affects an-
giogenesis in mammals45 and, similarly in fish, affects for-
mation of the subintestinal vessels and eye development.46
The measurement of FITC in peripheral vessels is therefore
potentially problematic. Similarly, FITC measurements in
the heart can be obscured by accumulation of dextran in the
pericardial sac, particularly in cases of edema. To minimize
any potential confounding effects on FITC measurements
and to allow normalization to baseline values, measurements
of FITC were determined in the dorsal aorta, as similarly
performed by Rider et al.40
As podocytes exhibit elaborate primary processes and nu-
merous interdigitating foot processes by 3 dpf,26 this age was
selected for the injection of compounds to induce pharmaco-
logical injury. Edema is readily observed as a result of acute
renal failure in larval fish.21,39,40,47 The concentration of pu-
romycin was partially based on previous studies,39 and fol-
lowing preliminary studies, three concentrations of adriamycin
were tested. One hundred percent survival was observed at
both tested doses of puromycin (5 or 25mg mL-1). Only the
higher dose of puromycin resulted in edema (Fig. 1A), which
was observed from 24h in 45% of fish (Fig. 1B).
The higher doses of adriamycin (2 and 4mg mL-1) de-
creased survival to 90% after 24 h. Two milligrams per mil-
liliter adriamycin resulted in transient edema in >10% of fish,
conversely 4mg mL-1 resulted in persistent edema in 75% of
larvae, some of which had remaining yolk reserves sugges-
tive of stunted development (Fig. 1A, C). Due to the mortality
and gross morphological changes associated with the highest
dose of adriamycin, only 1 and 2mg mL-1 concentrations
were taken forward for further study.
Effects of puromycin and adriamycin on renal
permeability and cardiovascular function
Both puromycin12 and adriamycin15 are known to disrupt
the GFB inmammals.While the effect of injected adriamycin
on developed podocytes is untested in fish, puromycin has
been shown to disrupt the fish GFB.39 Puromycin and
adriamycin were compared as pharmacological podocyte
injury models in larval fish by testing both target effects
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on glomerular permeability and side effects on cardiovas-
cular function.
Only the 25-mg mL-1 dose of puromycin resulted in in-
creased clearance of injected 70 kDa dextran (Fig. 2A).
Neither 1 nor 2mg mL-1 adriamycin resulted in any in-
creased clearance of 70 kDa dextran up to 96 hpi (Fig. 2B).
The first derivative of puromycin-induced dextran clearance
from the dorsal aorta shows that in all groups, the rate of
change is highest over the initial 24 h postinjection (Fig. 2C).
This is expected to be due to the continuing maturation
of podocytes and the GFB structure between 3 and
4 dpf.22,23,26,32 Over the first 24 h, the 25-mg mL-1 dose of
puromycin significantly increased the rate of loss of injected
dextran compared with controls (Fig. 2C). The effect of in-
creased dextran excretion by 25mg mL-1 puromycin was
also observed in fish injected at 4 dpf (Fig. 2D).
Despite having no effect on dextran clearance, the highest
tested dose of adriamycin (2mg mL-1) significantly de-
creased the heart rate (Fig. 2E) and blood flow (Fig. 2F). The
highest dose of puromycin (25mg mL-1) had no effect on
heart rate, but reduced venous blood flow (Fig. 2F). Due to
the lack of effect of adriamycin on dextran clearance and its
side effects on heart rate and blood flow, this compound was
not further assessed. Conversely, with its impact on dextran
clearance, puromycin was further evaluated for its effects on
podocyte ultrastructure.
Analysis of puromycin-induced ultrastructural
changes in the GFB
To assess podocyte structure after 25mg mL-1 puromycin
injection, the ultrastructure of the GFB was quantitatively
analyzed as performed by Benchimol et al. (Fig. 3A).44 Well-
developed primary and secondary foot processes, SDs, and
a trilaminar GBM were clearly visible at 4 dpf in healthy
zebrafish glomeruli (Fig. 3B, C). Focal podocyte effacement,
the loss of filtration slits, and enlargement of the foot process
area in contact with the GFB were observed as a result of
25mg mL-1 puromycin (Fig. 3D, E). To estimate the time
point at which podocyte effacement occurs, samples were
taken at 8 and 24 hpi. Foot process frequency (Fig. 3F) and
foot process width (Fig. 3G) were not significantly altered
until 24 hpi, suggesting that significant puromycin-induced
podocyte effacement likely occurs between 8 and 24 hpi.
Measurement of dextran excretion dynamics using
a modified 96-well plate assay
Our validated puromycin injury model was used to test a
novel assay we developed to minimize fish handling and to
allow the dynamics of glomerular permeability to be mea-
sured in a semihigh-throughput manner. This method allows
up to 48 fish to be studied simultaneously (Fig. 4A, B). The
loss of glomerular selectivity by 25mg mL-1 puromycin was
also confirmed by our excretion assay (Fig. 4C). As similarly
observed with the assay of FITC-dextran clearance from the
dorsal aorta, the mean first derivative of the excretion assay
shows that changes in dextran clearance are highest within
24 h of puromycin injection (Fig. 4D). This suggests that
functional changes in the podocytes begin within 24 h post-
injection.
Discussion
The utility of acute pharmacological glomerular injury
models would be greatly increased if they induced podocyte
regeneration and the subsequent dynamics of GFB repair
FIG. 1. Determination of pharmacological injury doses—1 nL injection at 3 dpf. (A) Representative images showing
pericardial edema (arrows) and remaining yolk reserves (*) presented in a portion of larvae administered adriamycin or
puromycin. (B) Five milligrams per milliliter puromycin does not result in edema. Increasing the puromycin dose to 25mg
mL-1 causes edema in >40% of fish from 24 hpi (mean– SEM). (C) Four milligrams per milliliter adriamycin causes edema
in >75% of larvae by 24 hpi (mean –SEM). SEM, standard error of the mean; dpf, days postfertilization; hpi, hours
postinjection.
4 RIDER ET AL.
could be monitored. Unlike in human disease and experi-
mental rodent models, zebrafish podocytes retain their re-
generative capacity throughout their entire lifecycle.35–37
Current models of acute pharmacological podocyte injury in
larval fish are limited by terminal edema. Edema is likely
caused by a reduced renal flow, which impairs ion homeo-
stasis due to a disruption in tubular ion uptake.39,46,48
To further the development of pharmacological glomeru-
lar injury methods in larval zebrafish, specific and off-target
effects of puromycin and adriamycin were compared to
identify a suitable compound for the induction and resolution
of glomerular injury. To discriminate against effects arising
from impaired podocyte development, podocyte toxins were
administrated at 3 dpf. At this age,*70% the GBM is cov-
ered with organized podocyte foot processes and SDs, and the
GFB is capable of selective filtraiton.22,26,39 To track the
dynamics of glomerular function, we developed a novel assay
to monitor the onset and resolution of abnormal protein fil-
tration arising from podocyte injury and repair.
Rodent models of adriamycin nephropathy are well es-
tablished and characterized by increased protein excretion,
tubulointerstitial inflammation, and fibrosis.15,49 In larval
fish, waterborne adriamycin administered from 9 to 48 h
postfertilization (hpf) impairs the establishment of discrim-
inative filtration due to abnormal podocyte development.46
Waterborne delivery of adriamycin is also associated with
off-target toxicity, particularly to the heart.15,46,50 We aimed
to reduce off-target effects by using a more direct delivery of
adriamycin by intravenous microinjection, as similarly used
in the rodent adriamycin nephropathy model.15 In our model
FIG. 2. Comparison of adriamycin and puromycin as agents for podocyte injury. (A) Mean (–SEM) dextran clearance is
significantly increased by injection of 25mg mL-1, but not by 5mg mL-1, puromycin at 3 dpf (n = 8). (B) Neither 1 nor 2mg
mL-1 adriamycin injected at 3 dpf has a significant effect on mean (–SEM) dextran clearance (n = 8). (C) First derivative of
(A) showing the rate change in dextran clearance is greatest within the first 24 hpi with the first derivative of 25mg mL-1
puromycin being significantly greater than both controls and 5mg mL-1-treated fish. (D) 25mg mL-1 puromycin injected at
4 dpf also significantly decreases mean (–SEM) dextran clearance 24 hpi. (E) 2mg mL-1 adriamycin significantly reduces
mean (–SEM) heart rate, and puromycin has no effect (n = 8). (F) Mean (–SEM) venous blood flow is decreased by
both 2mg mL-1 adriamycin and 25mg mL-1 puromycin (n = 8). Two-way ANOVA, p-value summary: *<0.05; **£0.002;
***£0.0002.
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assessing the effects of injected adriamycin in older larval
fish with a functional glomerulus, the clearance of coinjected
70 kDa dextran was likely confounded by off-target cardio-
vascular effects.
The pronephric glomerular arterioles of zebrafish branch
directly off the dorsal aorta, thus glomerular flow is tightly
associated with flow in the central vasculature.29,40 In the
present study, the adriamycin-induced reduction in heart rate
and blood flowmay have decreased glomerular flow rates and
masked any increase in dextran clearance resulting from
podocyte damage. Due to confounding off-target cardiovas-
cular effects, adriamycin was considered unsuitable for
modeling glomerular injury in zebrafish older than 3 dpf.
The injection of puromycin at 3 or 4 dpf in zebrafish larvae
has been shown to result in podocyte effacement, loss of
glomerular selectivity, and terminal edema.39,51 To mitigate
off-target effects and edema, a lower dose of puromycin (5mg
mL-1) was tested, but was found insufficient for the measur-
able induction of glomerular injury. By injecting 1 nL of 25mg
mL-1 puromycin, as opposed to the 2.3–4.6-nL volume used
by used Hentschel et al.,39 we observed similar effects on
dextran clearance and podocyte effacement, including the
onset of terminal edema. Injection volumes were restricted to
1 nL for the avoidance of negative effects on cardiovascular
function, which can arise when injecting larger volumes into
the circulation of larval fish (unpublished).
We employed image analysis44 to quantitate podocyte foot
process width and foot process frequency. The quantification
of podocyte morphology established that measurable struc-
tural changes occur between 8 and 24 hpi.
At a dose causing disruption of the GFB, puromycin also
reduced blood flow by 24 hpi. Although decreased blood flow
was observed, a higher dextran clearance was still detected,
indicating a robust effect of puromycin on glomerular per-
meability. Previous studies have shown that FITC-dextran
intensity in the vasculature is not significantly affected by
edema-induced volume expansion.39 The dose of puromycin
established for acute podocyte injury was not associated
with any measurable effects on tubular structure (data not
shown), including the brush border. The cilia of tubular cells
that form the zebrafish nephron are essential for fluid clear-
ance.52 This suggests that in the pronephros, effects of pu-
romycin are specific to the glomerulus, as similarly reported
by Hentschel et al.39
FIG. 3. Effect of intravenous
puromycin injection at 3 dpf on
GFB structure (n= 3–4). (A)
Image analysis of GFB for
determination of podocyte ef-
facement. Black double line=
total length of GBM. White
lines= foot process width. (B,
C) Representative transmis-
sion electron microscopy mi-
crographs at 24 hpi showing
normal GFB structure with
primary (*) and secondary foot
processes with slit diaphragms
(arrows). Foot process mor-
phology is not significantly
different from that of shamfish
at 8 hpi (data not shown).
(D, E) 25mg mL-1 puromycin
results in patchy podocyte ef-
facement (white brackets). (F)
Administration of 25mg mL-1
puromycin significantly de-
creases the mean (–SEM)
number of foot processes per
unit length of GBM ( p=
0.005) and (G) mean (–SEM)
foot process width ( p= 0.04).
Analysis by one-way ANOVA
with post hoc Dunnet’s test.
Scale bars are all 0.5lm.GFB,
glomerular filtration barrier;
GBM, glomerular basement
membrane. p-value summary:
*< 0.05; **£ 0.002.
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To advance methods for the in vivo analysis of glomerular
permeability in zebrafish, we developed a novel assay of
dextran excretion allowing the continuous monitoring of
glomerular permeability to high-molecular-weight (HMW)
molecules. Repeated handling and anesthesia of fish induce
stress responses and cause detrimental effects on cardiovas-
cular function.41,53,54 This limits the frequency and precision
at which FITC-dextran clearance may be measured from
the vasculature of larval fish. Hence, an advantage of our
semihigh-throughput plate assay is that after injection of
FITC-dextran, it involves no further handling or anesthesia
of fish. This dextran excretion assay complemented mea-
surements of FITC-dextran clearance from the dorsal aorta
and confirmed that increased excretion of HMW molecules
occurred in the first 24 h after injection of puromycin. While
our dextran assays suggest that in some individuals glomer-
ular function may resolve by 48 hpi, systemic effects leading
to terminal edema were not resolved, as reported in previous
studies.39
Puromycin- or adriamycin-induced nephrosis are among
the oldest and most widely used models of human nephrotic
syndrome, particularly using rats due to their susceptibility to
both compounds.55 This study has identified the suitability of
puromycin for induction of acute podocyte injury in zebrafish
larvae. As observed in rodent models, the defined single dose
of puromycin used in the present study results in podocyte
effacement with a concurrent loss of glomerular selectivity.
The onset of GFB changes within 24 h in fish is considerably
faster than occurs in rodent models, which have a 4–5-day
latency period after puromycin injection.12,13,56
In contrast to rodent models, puromycin administration in
larval fish results in off-target effects on central blood flow,
which may result in the terminal onset of edema.39 Further
studies are required to assess the correlation between edema
and GFB changes to establish if puromycin-induced injury is
recoverable in larval fish, as observed in the genetic podocyte
NTR-based podocyte injury model.35,37 A pharmacological
glomerular injury model is yet to be established in adult zeb-
rafish. Unlike larval fish, which can only repair their single
paired nephron, glomerular injury in adult fish may induce
neonephrogenesis, as documented with tubular injury.36,57
Our novel excretion assay for the monitoring of glomerular
selectivity, a proxy of podocyte function, enables a semihigh-
throughput and dynamic measurement of glomerular filtration
without the confounding effects of repeated fish handling. This
will facilitate the screening of small molecules that prevent
glomerular injury or promote podocyte repair. The ability to
measure the dynamics of GFB function provides an excellent
tool for the in vivo analysis of glomerular injury and podocyte
repair in larval zebrafish.
FIG. 4. Plate assay to measure dynamics of cleared 70 kDa FITC-dextran following puromycin injection at 3 dpf (n = 14).
(A) Photo of modified 96-well plate with 48 paired wells. White arrow pointing toward 250-lm slits between paired wells.
(B) Schematic of well pairing. A single fish injected with FITC-dextran is placed in well 1. FITC fluorescence from excreted
dextran is assayed in well 2. (C) Twenty-five milligrams per milliliter puromycin significantly increases mean (–SEM)
clearance of 70 kDa FITC-dextran over 48 hpi. Analysis of linear regression slopes shows that both are significantly
different ( p = < 0.0001). (D) The mean (–SEM) first derivative of puromycin-treated fish between 0 and 24 hpi is 149 – 49.4
higher than vehicle-treated fish. This is maintained, although to a lesser extent, over 24–48 hpi where the mean first
derivative of puromycin-treated fish is 87.4 – 34.2 higher than control fish. T-test, p-value: *<0.02; **<0.006.
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